CERo Therapeutics (CERO) announces that the company has issued additional shares of its Series D Preferred Stock to certain institutional investors pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8M, including $5M previously issued in April and up to $3M issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company’s common stock. The gross proceeds to CERo from today’s closing are expected to be approximately $750,000, with up to $2.25M of cash that may be funded at one or more additional closings, at the election of the Investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Expands Leadership with New Executive Roles
- Cero announces two granted U.S. patents, European patent application allowance
- Promising Developments in CERo Therapeutics’ Novel AML Therapy Underpin Buy Rating
- Cero Therapeutics doses first patient with CER-1236 in Phase 1 trial
- Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital